<DOC>
	<DOCNO>NCT02171221</DOCNO>
	<brief_summary>This first-in-human , open label , single arm , sequential dose escalation expansion study oral DFP-11207 patient advance solid tumor .</brief_summary>
	<brief_title>Phase I Study Oral DFP-11207 Solid Tumors</brief_title>
	<detailed_description>DFP-11207 investigational agent demonstrate reasonable antitumor activity preclinical animal tumor model . The DFP-11207 drug product supply oral capsule take daily 28 day 28-day treatment cycle .</detailed_description>
	<mesh_term>Antimetabolites , Antineoplastic</mesh_term>
	<criteria>1 . Patients must pathologicallyconfirmed solid tumor , refractory standard therapy disease conventional systemic chemotherapy reliably effective effective therapy available . 2 . Aged ≥ 18 year . 3 . ECOG Performance Status 0 1 . 4 . Adequate clinical laboratory value define : absolute neutrophil count ≥ 1.5 x 10^9/L platelet ≥ 100 x 10^9/L plasma creatinine ≤ 1.5 x upper limit normal ( ULN ) institution bilirubin ≤ 1.5 x ULN alanine transaminase ( ALT ) aspartate transaminase ( AST ) &lt; 2.5 x ULN ( &lt; 5 x ULN document hepatic metastasis ) 5 . Absence uncontrolled intercurrent illness , include uncontrolled infection , cardiac condition , organ dysfunction . 6 . Patients may measurable nonmeasurable disease define RECIST 1.1 . 7 . Signed informed consent prior start study specific procedure . 8 . Women childbearing potential must negative serum urine pregnancy test . Male female patient must agree use acceptable contraceptive method duration study least one month last drug administration . 1 . Known allergy fluoropyrimidines know dihydropyrimidine dehydrogenase ( DPD ) deficiency . 2 . Patients exclude receive previous chemotherapy , immunotherapy , radiotherapy investigational therapy within 4 week ( 6 week nitrosoureas mitomycin C ) 5 halflives noncytotoxic agent prior study entry . 3 . Extensive prior radiotherapy , 30 % bone marrow reserve , prior bone marrow/stem cell transplantation . 4 . Any concomitant condition opinion Investigator could compromise objective study patient 's compliance . 5 . Pregnant lactating individual . 6 . Current malignancy another type , exception adequately treat situ cervical cancer , squamous cell basal cell skin cancer malignancy evidence disease 2 year . 7 . Known history HIV , HBV HCV infection . 8 . Documented known bleeding disorder . 9 . Requirement anticoagulation treatment increase international normalized ratio ( INR ) activate partial thromboplastin time ( aPTT ) normal range ( low dose deep vein thrombosis ( DVT ) line prophylaxis allow ) . 10 . Clinically evident central nervous system metastases leptomeningeal disease control prior surgery radiotherapy ; history seizure disorder control antiseizure medication time enrollment . 11 . Cardiac dysfunction define myocardial infarction within 6 month study entry , New York Heart Association Class III IV heart failure , uncontrolled dysrhythmias poorly control angina . 12 . History serious ventricular arrhythmia ( VT VF , ≥ 3 beat row ) , QTc ≥ 450 msec men 470 msec woman , LVEF ≤ 40 % MUGA ECHO .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Refractory relapse tumor</keyword>
	<keyword>Antimetabolites , Antineoplastic</keyword>
	<keyword>Fluorouracil</keyword>
</DOC>